Drugs / Live Attenuated Poliomyelitis Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06752174 Background | Mar 2023 → Apr 2024 | poliomyelitis | Beijing Minhai Biotechnology Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Live Attenuated Poliomyelitis Vaccine | “The goal of this clinical trial is to evaluate the immunogenicity and safety of a Sabin Inactivated Poliomyelitis Vaccine (sIPV) and a commercially available Live Attenuated...” NCT06752174 ↗ |
| Known as | bOPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06752174 ↗ |
| Modality | Vaccine | “Live Attenuated Poliomyelitis Vaccine” NCT06752174 ↗ |